Alector announces fda fast track designation granted to al001 for the treatment of patients with frontotemporal dementia

Alector, inc. announced that the u.s. food and drug administration (fda) has granted fast track designation for its investigational therapeutic, al001, for the treatment of patients with frontotemporal dementia (ftd) carrying specific genetic mutations in the granulin gene (ftd-grn). al001 is the company’s product candidate currently being evaluated in a phase 2 trial for the treatment of ftd-grn and ftd-c9orf72. fast track designation is designed to facilitate the development and expedite the review of therapies for serious conditions and fill an unmet medical need. programs with fast track designation may benefit from early and frequent communications with the fda, potential priority review, and additionally a rolling submission of the marketing application.
ALEC Ratings Summary
ALEC Quant Ranking